Lymphoma Trial, Recruiting NCT03932903 Sponsor: Northwestern University Condition: Lymphoma
Back to Lymphoma

Lymphoma Trial, Recruiting

NCT03932903
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For young people (AYA participants):

  • People aged 14 to 29 years old
  • People who have been diagnosed with acute lymphoblastic leukemia (ALL) or lymphoma (cancers affecting blood cells or the lymphatic system)
  • People who are in the maintenance phase of their treatment, have finished at least one cycle of it, and have at least one more month of maintenance treatment still to go
  • People whose doctor has prescribed a medication called 6-mercaptopurine (6MP) as part of their treatment
  • People who are able to communicate in English
  • For those under 18, a parent or caregiver must be able to provide consent on their behalf

For caregivers:

  • People who have been nominated by the young person (AYA participant) as a primary caregiver involved in their cancer care — this could be a parent, relative, partner, or friend
  • People who are able to communicate in English

Who may not be able to join:

For young people (AYA participants):

  • People with cognitive impairments that the medical team determines would make it too difficult to complete the study tasks or measures
  • People who do not meet the inclusion criteria listed above

For caregivers:

  • People who do not meet the inclusion criteria listed above

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Alexandra M Psihogios, Ph.D., Northwestern University

Phone: 312-503-3577

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
31 July 2025
Est. completion
31 July 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Technical Difficulties; Retention Rate; Screening Rate; Intervention Engagement; Recruitment Rate; Intervention Acceptability

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov